Liquidia Technologies (NASDAQ:LQDA)‘s stock had its “buy” rating restated by equities researchers at Wedbush in a report released on Wednesday, January 16th. They presently have a $47.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 222.80% from the stock’s current price.
A number of other analysts have also issued reports on the company. Zacks Investment Research lowered Liquidia Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, December 5th. Cowen set a $40.00 price target on Liquidia Technologies and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Jefferies Financial Group began coverage on Liquidia Technologies in a research note on Thursday, November 8th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Needham & Company LLC set a $32.00 price objective on Liquidia Technologies and gave the stock a “buy” rating in a research report on Wednesday, October 31st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $36.50.
Shares of LQDA opened at $14.56 on Wednesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.27 and a current ratio of 6.27. Liquidia Technologies has a 12 month low of $10.52 and a 12 month high of $38.46.
Institutional investors have recently made changes to their positions in the stock. Canaan Partners VIII LLC purchased a new stake in Liquidia Technologies in the fourth quarter valued at $55,521,000. NEA Management Company LLC purchased a new stake in Liquidia Technologies in the third quarter valued at $68,193,000. FMR LLC purchased a new stake in Liquidia Technologies in the third quarter valued at $6,729,000. BlackRock Inc. raised its position in Liquidia Technologies by 7.1% in the fourth quarter. BlackRock Inc. now owns 231,400 shares of the company’s stock valued at $5,011,000 after purchasing an additional 15,415 shares during the period. Finally, Vanguard Group Inc purchased a new stake in Liquidia Technologies in the third quarter valued at $4,263,000. Hedge funds and other institutional investors own 43.64% of the company’s stock.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
See Also: Coverage Ratio
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.